Biotron Ltd
ASX:BIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Jiangxi Synergy Pharmaceutical Co Ltd
SZSE:300636
|
CN |
|
Ortel Communications Ltd
NSE:ORTEL
|
IN |
Biotron Ltd
Operating Income
Biotron Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biotron Ltd
ASX:BIT
|
Operating Income
-AU$2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
13%
|
CAGR 10-Years
5%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Operating Income
-$73.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
|
CSL Ltd
ASX:CSL
|
Operating Income
$4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Operating Income
-AU$8.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Operating Income
AU$30.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Operating Income
-AU$46.4m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-23%
|
|
Biotron Ltd
Glance View
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.
See Also
What is Biotron Ltd's Operating Income?
Operating Income
-2m
AUD
Based on the financial report for Dec 31, 2025, Biotron Ltd's Operating Income amounts to -2m AUD.
What is Biotron Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
5%
Over the last year, the Operating Income growth was -37%. The average annual Operating Income growth rates for Biotron Ltd have been -6% over the past three years , 13% over the past five years , and 5% over the past ten years .
